Immunotherapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy

A Case-Based Program: Immunotherapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy

Sunday, October 21
12:15 PM - 1:15 PM
Location: Session Room 216 A/B

Treating patients with unresectable Stage III NSCLC requires a multidisciplinary approach, with the radiation oncologist playing a pivotal role in the treatment pathway. This interactive, case-based presentation will review the patient journey for Stage III NSCLC, from diagnosis to chemoradiation treatment and available options for improving patient outcomes following the completion of chemoradiation therapy.

Company: AstraZeneca
Contact: Christina Mahon
Phone: 609-694-6426
Email: christina.mahon1@astrazeneca.com


Assets

A Case-Based Program: Immunotherapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for A Case-Based Program: Immunotherapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy